A Weekly Injection to Simplify Parkinson’s Treatment?

Scientists at the University of South Australia (UniSA) have developed a once-weekly, biodegradable injection that steadily delivers levodopa and carbidopa—two cornerstone medications used to manage Parkinson’s disease symptoms. 🧠 Why This Matters for People with Parkinson’s Parkinson’s disease is a progressive neurological condition that causes symptoms like tremors, stiffness, and slowed movement. People living with Parkinson’s often need to take medications multiple times a day to manage these symptoms. This frequent dosing can be difficult—especially for older adults or those who have trouble swallowing—and may lead to fluctuating drug levels, reduced effectiveness, and side effects. This new long-acting injectable is designed to ease that burden by maintaining consistent levels of medication for seven days, reducing the need for daily pills. 🔬 How It Works The injection is given just under the skin or into muscle using a fine needle (no surgery needed). It forms a temporary implant that gradually releases medication over one week. The formulation is made from FDA-approved biodegradable materials that break down safely in the body. 📊 Promising Lab Results 90% of the levodopa and over 80% of the carbidopa was steadily released over seven days. The implant naturally broke down by more than 80% within a week. No toxicity was found in lab safety tests. Can be delivered using a standard 22-gauge needle. 🌍 Future Possibilities Beyond Parkinson’s This injectable system may also benefit people with other long-term conditions like cancer, diabetes, infections, and other neurodegenerative diseases, where steady drug levels are important. 🚀 What’s Next? The formulation has been filed for an Australian patent, and the research team is now preparing for clinical trials. They also hope to adapt the technology to allow drug release over different time periods—such as multiple days or several weeks. “We’re not just improving how the drug is delivered,” said lead researcher Professor Sanjay Garg, “we’re improving patients’ lives.” 💡 Why This Gives Hope This innovation could be a meaningful step forward for people with Parkinson’s disease—especially those seeking simpler, more consistent, and less burdensome treatment options. While more testing is needed, it highlights the power of pharmaceutical innovation in improving daily life for those living with chronic conditions.